Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ:ZBIO) pursuant and/or traceable to the Company's September 2024 initial public offering ("IPO"). Investors who suffered significant losses are encouraged to contact the firm. [Click here for information about joining the class action] CASE OVERVIEW: Zenas BioPharma, a clinical-stage biopharmaceutical company, held ...